Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Switzerland
/
Pharmaceuticals & Biotech
Create a narrative
Novartis Community
SWX:NOVN Community
1
Narratives
written by author
0
Comments
on narratives written by author
110
Fair Values set
on narratives written by author
Create a narrative
Novartis
Popular
Undervalued
Overvalued
Community Investing Ideas
Novartis
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
Pluvicto And Radioligand Pipeline Will Expand Future Markets
Key Takeaways Novartis' innovative drug launches and radioligand therapy pipeline position it for significant growth and revenue diversification. Strong market penetration and sales of drugs like Kisqali, coupled with U.S. investment, support long-term net margin and EPS growth.
View narrative
CHF 98.36
FV
5.7% undervalued
intrinsic discount
1.94%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
78
users have followed this narrative
about 11 hours ago
author updated this narrative
Your Valuation for
NOVN
NOVN
Novartis
Your Fair Value
CHF
Current Price
CHF 92.73
6.3% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
58b
2015
2018
2021
2024
2025
2027
2030
Revenue US$58.3b
Earnings US$14.1b
Advanced
Set Fair Value